USCCB Statement on the Supreme Court’s Abortion Pill Decision
Boxes of Mifepristone, the first pill in a medical abortion, are seen at Alamo Women's Clinic in Carbondale, Illinois, April 20, 2023. The U.S. Supreme Court dismissed a challenge to the rules for the availability of the abortion drug mifepristone in a unanimous decision on June 13, 2024. (OSV News photo/Evelyn Hockstein, Reuters)
LOUISVILLE, Kentucky -- In response to the decision by the Supreme Court of the United States today on FDA v. Alliance for Hippocratic Medicine the U.S. Conference of Catholic Bishops (USCCB) offered the following statement from its spokesperson, Chieko Noguchi, executive director of public affairs.
“Today’s Court ruling on procedural grounds will continue to put the health of women and girls at risk. As the USCCB’s pro-life chairman has said, abortion is not health care. The Church will continue to advocate for women’s health and safety, and to lovingly serve mothers in need.”
"Today’s Court ruling on procedural grounds will continue to put the health of women and girls at risk."
06/13/2024 |
In a unanimous opinion written by Justice Brett Kavanaugh, the court found in FDA v. Alliance for Hippocratic Medicine that the "plaintiffs lack Article III standing to challenge FDA's actions regarding the regulation of mifepristone."
06/13/2024 |
"Así que después de dos años, todavía hay motivos para celebrar porque sabemos que la gracia de Dios es más poderosa que todo esto, pero también, tenemos que aceptar el reto que tenemos ante nosotros", obispo Michael F. Burbridge dijo.
06/13/2024 |
Load More
